CD19 and hematologic disorder: Furthermore, Mikolič et al. showed that incorporation of the TLR4 domain into the 2nd generation CAR targeting CD19 resulted in increased CAR T-cell cytotoxicity and activation, while it could also lead to CD19 CAR sustainability in both hematologic malignancies and solid tumor models.